Search tips
Search criteria 


Logo of arthrestherBioMed Centralbiomed central web sitesearchsubmit a manuscriptregisterthis articleArthritis Research & Therapy
Published online 2010 May 14. doi: 10.1186/ar3013

Table 2

Clinical features of the participants who contributed synovial fluid

Number of participants3030
Sex, male/female6/246/24
Age, mean (range)63.1 (32 to 88)75.3 (67 to 89)
Disease duration (y), mean (range)13.0 (0.5 to 50)NA
Positive anti-CCP antibody, n (%)10 (83.3%)NA
ESR (mm), mean (range)49.6 (4 to 116)NA
CRP (mg/dl), mean (range)3.1 (0 to 13.9)NA
MMP3 (ng/ml), mean (range)362.7 (43.2 to 800)NA
DAS28, mean (range)4.9 (2.2 to 7.1)NA
 SJC, mean (range)4.9 (0 to 17)NA
 TJC, mean (range)5.1 (0 to 27)NA
VAS52.1 (10 to 95)NA
Steinbrocker Stage, nI: 3, II: 3, III: 5, IV: 19NA
Steinbrocker Class, nI: 1, II: 22, III: 7, IV: 0NA
Kellgren/Lawrence grade, nNAI: 0, II: 0, III: 11, IV: 19
Medication, n (%)
 Prednisolone20 (67%)NA
 Methotrexate15 (50%)NA
 Infliximab3 (10%)NA
 Eternercept1 (3.3%)NA
 Tocilizumab0 (0%)NA
 Tacrolimus2 (6.7%)NA
 Salazosulfapyridine8 (27%)NA
 Bucillamine6 (20%)NA
 Mizoribine1 (3.3%)NA
 Gold2 (6.7%)NA

CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentaition ratio; MMP-3, metalloproteinase-3; NA, not applicable; OA, osteoarthritis; RA, rheumatoid arthritis; SJC, swollen joint count score; TJC, tender joint count; VAS, visual analogue scale of general health.

¶anti-CCP antibodies of 10 patients were positive among 12 patients examined.